BIIB - Comparative Study: Biogen And Industry Competitors In Biotechnology Industry | Benzinga
In today's rapidly changing and highly competitive business world, it is imperative for investors and industry observers to carefully assess companies before making investment choices. In this article, we will undertake a comprehensive industry comparison, evaluating Biogen (NASDAQ:BIIB) vis-à-vis its key competitors in the Biotechnology industry. Through a detailed analysis of important financial indicators, market standing, and growth potential, our goal is to provide valuable insights and highlight company's performance in the industry.
Biogen Background
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| Biogen Inc | |||||||
| 22.74 | |||||||
| 2.29 | |||||||
| 3.33 | |||||||
| -0.47% | |||||||
| $0.05 | |||||||
| $1.87 | |||||||
| 0.87% | |||||||
| AbbVie Inc | |||||||
| 38.11 | |||||||
| 20.30 | |||||||
| 4.48 | |||||||
| 14.25% | |||||||
| $4.74 | |||||||
| $7.44 | |||||||
| -5.97% | |||||||
| Amgen Inc | |||||||
| 18.80 | |||||||
| 18.47 | |||||||
| 5.30 | |||||||
| 23.97% | |||||||
| $3.6 | |||||||
| $5.1 | |||||||
| 3.77% | |||||||
| Gilead Sciences Inc | |||||||
| 16.04 | |||||||
| 4.18 | |||||||
| 3.45 | |||||||
| 10.03% | |||||||
| $3.23 | |||||||
| $5.49 | |||||||
| 0.11% | |||||||
| Vertex Pharmaceuticals Inc | |||||||
| 26.29 | |||||||
| 5.46 | |||||||
| 9.44 | |||||||
| 6.47% | |||||||
| $1.23 | |||||||
| $2.16 | |||||||
| 6.39% | |||||||
| Regeneron Pharmaceuticals Inc | |||||||
| 22.76 | |||||||
| 3.49 | |||||||
| 6.93 | |||||||
| 4.12% | |||||||
| $1.23 | |||||||
| $2.93 | |||||||
| 14.53% | |||||||
| BioNTech SE | |||||||
| 7.86 | |||||||
| 1.06 | |||||||
| 3.24 | |||||||
| 0.81% | |||||||
| $0.27 | |||||||
| $0.24 | |||||||
| -74.13% | |||||||
| Genmab A/S | |||||||
| 32.11 | |||||||
| 4.39 | |||||||
| 8.10 | |||||||
| 7.11% | |||||||
| $2.71 | |||||||
| $4.64 | |||||||
| 16.08% | |||||||
| Biomarin Pharmaceutical Inc | |||||||
| 115.06 | |||||||
| 3.41 | |||||||
| 7.33 | |||||||
| 0.83% | |||||||
| $0.07 | |||||||
| $0.46 | |||||||
| 15.04% | |||||||
| Incyte Corp | |||||||
| 28.12 | |||||||
| 2.40 | |||||||
| 3.30 | |||||||
| 3.54% | |||||||
| $0.23 | |||||||
| $0.86 | |||||||
| -3.73% | |||||||
| Neurocrine Biosciences Inc | |||||||
| 59.48 | |||||||
| 5.55 | |||||||
| 6.38 | |||||||
| 4.31% | |||||||
| $0.12 | |||||||
| $0.49 | |||||||
| 28.59% | |||||||
| United Therapeutics Corp | |||||||
| 12.75 | |||||||
| 1.90 | |||||||
| 5.19 | |||||||
| 4.92% | |||||||
| $0.36 | |||||||
| $0.53 | |||||||
| 27.76% | |||||||
| Exelixis Inc | |||||||
| 74.52 | |||||||
| 2.86 | |||||||
| 3.95 | |||||||
| 0.04% | |||||||
| $-0.01 | |||||||
| $0.45 | |||||||
| 14.62% | |||||||
| Grifols SA | |||||||
| 237.54 | |||||||
| 0.99 | |||||||
| 0.93 | |||||||
| 0.99% | |||||||
| $0.25 | |||||||
| $0.63 | |||||||
| 3.66% | |||||||
| Average | |||||||
| 53.03 | |||||||
| 5.73 | |||||||
| 5.23 | |||||||
| 6.26% | |||||||
| $1.39 | |||||||
| $2.42 | |||||||
| 3.59% |